Instituto Butantan is a Brazilian biologic research center located in Butantã, in the western part of the city of São Paulo, Brazil
The Latest Bing News on:
Instituto Butantan Research
- Valneva Reports Nine-Month 2021 Revenue and Cash
Cash and cash equivalents of €247.9 million at the end of September 2021. Reflects $107.6 million of gross proceeds raised in a US IPO and placement i ...
- Valneva to Present its Chikungunya Vaccine Candidate at the ASTMH 2021 Annual Meeting
February 2020 3 Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries 4 CEPI awards up to $23.4 million to Valneva for late ...
- Valneva to Present its Chikungunya Vaccine Candidate at the ASTMH 2021 Annual Meeting
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it will present its Chikungunya vaccine candidate, VLA1553, on November 18 and 19, 2021 during the American ...
- Valneva to Present its Chikungunya Vaccine Candidate at the ASTMH 2021 Annual Meeting
To make VLA1553 more accessible to Low and Middle Income Countries (LMIC), Valneva and Instituto Butantan in Brazil ... results and completion of research, development and clinical trials for ...
- China's Sinovac vaccine is 50,38% effective according to leading Brazilian research center
The Instituto Butantan, the São Paulo-based research institute responsible for developing the vaccine and conducting trials in the country, announced last week the vaccine had a 78% overall ...
The Latest Google Headlines on:
Instituto Butantan Research
The Latest Bing News on:
Instituto Butantan Discovery
- PloS one
Generating evidence on screening, diagnosis and management of non-communicable diseases during pregnancy; a scoping review of current gap and practice in India with a comparison of Asian context.
- Valneva to Present its Chikungunya Vaccine Candidate at the ASTMH 2021 Annual Meeting
To make VLA1553 more accessible to Low and Middle Income Countries (LMIC), Valneva and Instituto Butantan in Brazil signed an agreement for the development, manufacturing and marketing of VLA1553 3.
- An agenda for forgotten diseases
Andricopulo is head of technology transfer at the Center for Innovation in Biodiversity and Drug Discovery (CIBFAR), one of the Research, Innovation, and Dissemination Centers (RIDC) funded by FAPESP, ...
The Latest Google Headlines on:
Instituto Butantan Discovery
